Healthcare Industry News:  analgesia 

Devices Surgery

 News Release - December 13, 2006

I-Flow Announces ON-Q Therapy Upheld as Best Practice for Post-Surgical Pain Relief in Pivotal Study

Independent Large-Scale Meta-Analysis Results Published in Prestigious Surgical Journal

LAKE FOREST, Calif.--(HSMN NewsFeed)--I-Flow Corporation (NASDAQ:IFLO ) announced today that a landmark meta-analysis confirming the efficacy of continuous wound catheters delivering local anesthetic, including ON-Q, for post surgical analgesia (pain relief) was published in the December 2006 Journal of the American College of Surgeons (JACS). The large-scale study encompassed 44 different randomized clinical trials which included 2,141 patients across a wide range of surgical procedures. JACS is a prominent peer-reviewed journal that is the official scientific publication of the American College of Surgeons.

The authors, from three world-class medical centers cited in the study, Cornell University, The Johns Hopkins University and Virginia Mason Medical Center, are encouraging widespread clinical use of the therapy. They arrived at this conclusion because their study compiled patient outcomes with continuous local anesthetic therapy as compared to narcotics, which is considered today's standard of care. Results with the ON-Q therapy included lower pain scores, decreased need for narcotics and narcotic intake, reduced narcotic side effects, higher patient satisfaction scores and a full day reduction in hospital length of stay.

According to the meta-analysis principal researcher and lead author, Spencer S. Liu, MD, these results are potentially significant due to the growing physician interest and patient need for better practices for post-surgical pain relief. Dr. Liu, of the Hospital for Special Surgery and the Weill College of Medicine of Cornell University, stated, "Recent surveys have shown that current techniques for treating post-surgical pain have met with modest success. This can translate into uncontrolled pain, resulting in a number of long-term negative outcomes." He continued by saying, "The results of this meta-analysis clearly identified continuous wound catheters delivering local anesthetic as providing improved pain relief, with consistent evidence of benefits across a wide range of surgical procedures. These findings coupled with the therapy's simplicity encourage both further investigation and increased clinical use."

"I-Flow has been committed to providing better post-surgical pain relief to the millions of patients undergoing surgery every year by offering ON-Q PainBuster as a significantly better alternative to narcotics," noted Donald M. Earhart, I-Flow's Chairman, President and Chief Executive Officer. "We are excited that the benefits of ON-Q that we have been advocating have been recognized in a study of this magnitude with scientific evidence that led to the publication in the Journal of American College Surgeons. We believe that the positive results of this meta-analysis will help surgeons, hospitals, insurance companies, managed care providers and other allied health professionals to better understand how ON-Q redefines recovery and gets patients back to normal faster," he added.

About ON-Q

ON-Q is now labeled to significantly reduce pain better than narcotics and to significantly reduce narcotics intake after surgery. ON-Q is a simple yet elegant device that consists of a small balloon pump that holds a local anesthetic (a pain-numbing medicine) and delivers it automatically through a tiny, specially designed tube (catheter) to provide even distribution of local anesthetic over a wider area, as compared to other catheters, because of its patented wicking capabilities.

Currently, more than 55 studies on the use of ON-Q have been completed and published or presented and more are underway to demonstrate the benefits of ON-Q in additional areas such as reduced infection risk, combination therapies (e.g., a local anesthetic and antibiotic mix, a combination of a local anesthetic and an anti-inflammatory), pediatrics and chronic pain. To learn more about the benefits of ON-Q visit

About I-Flow

I-Flow Corporation ( designs, develops and markets technically advanced, low cost drug delivery systems and services that are redefining the standard of care by providing life enhancing, cost effective solutions for pain relief.

"Safe Harbor" Statement

Certain disclosures made by the Company in this press release and in other reports and statements released by the Company are and will be forward looking in nature, such as comments that express the Company's opinions about trends and factors that may impact future operating results. Disclosures that use words such as the Company "believes", "anticipates", or "expects" or use similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ from those expected, and readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to republish revised forward-looking statements to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures made by the Company in this release, which seek to advise interested parties of the risks, and other factors that affect the Company's business, as well as in the Company's periodic reports on Forms 10-K, 10-Q and 8-K filed with the Securities and Exchange Commission. The risks affecting the Company's business include, among others: successful consummation of the previously announced sale of InfuSystem, Inc; physician acceptance of infusion-based therapeutic regimens; implementation of our direct sales strategy; dependence on our suppliers and distributors; reliance on the success of the home health care industry; our continuing compliance with applicable laws and regulations, such as the Food, Drug and Cosmetic Act, and the FDA's concurrence with our management's subjective judgment on compliance issues; the reimbursement system currently in place and future changes to that system; competition in the industry; economic and political conditions in foreign countries; currency exchange rates; inadequacy of booked reserves; technological changes; and product availability and acceptance. All forward-looking statements, whether made in this release or elsewhere, should be considered in context with the various disclosures made by the Company about its business.

Source: I-Flow

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.